Eledon Pharmaceuticals (ELDN) Gains from Investment Securities (2024 - 2026)
Eledon Pharmaceuticals (ELDN) posted Gains from Investment Securities of $19.0 million for Q1 2026, up 280.04% on a QoQ basis from -$10.5 million in Q4 2025, and up 288.49% year-over-year from $4.9 million in Q1 2025.
Eledon Pharmaceuticals (ELDN) Gains from Investment Securities (2024 - 2026) Analysis & Trends
Eledon Pharmaceuticals' Gains from Investment Securities history runs 3 years deep, the most recent figure standing at $19.0 million for Q1 2026.
- Quarterly Gains from Investment Securities rose 288.49% year-over-year to $19.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.4 million (up 91.85% YoY) and the FY2025 annual result came in at -$33.4 million, down 8.25% from the prior year.
- Gains from Investment Securities was $19.0 million for Q1 2026 at Eledon Pharmaceuticals, up from -$10.5 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $31.3 million in Q2 2024 and bottomed at -$96.4 million in Q3 2024.
- A 3-year average of -$7.3 million and a median of -$5.3 million in 2025 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2025 — Gains from Investment Securities tumbled 150.32% — and 2026, when it surged 288.49%.
- Eledon Pharmaceuticals' Gains from Investment Securities stood at $20.9 million in 2024, then tumbled by 150.32% to -$10.5 million in 2025, then surged by 280.04% to $19.0 million in 2026.
- Business Quant data shows ELDN's Gains from Investment Securities at $19.0 million in Q1 2026, -$10.5 million in Q4 2025, and -$564000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,380.63 Bn | 66,380.34 Bn | - |
| 2 | Nanobiotix | 1,910.39 Bn | 1,910.33 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 470.95 Bn | 466.16 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - |
| 8 | Argenx Se | 55.76 Bn | 50.58 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn |
| 10 | Eledon Pharmaceuticals | 401.92 Mn | 401.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.96 Mn |
| Mar 31, 2026 | 18.96 Mn |
| Dec 31, 2025 | -10.53 Mn |
| Dec 31, 2025 | -10.53 Mn |
| Sep 30, 2025 | -564,000.00 |
| Sep 30, 2025 | -564,000.00 |
| Jun 30, 2025 | -12.29 Mn |
| Jun 30, 2025 | -12.29 Mn |
| Mar 31, 2025 | -10.06 Mn |
| Mar 31, 2025 | -10.06 Mn |
| Dec 31, 2024 | 20.93 Mn |
| Dec 31, 2024 | 20.93 Mn |
| Sep 30, 2024 | -96.44 Mn |
| Sep 30, 2024 | -96.44 Mn |
| Jun 30, 2024 | 31.27 Mn |
| Jun 30, 2024 | 31.27 Mn |